Rockwell Medical, Inc. (NASDAQ:RMTI) Q3 2019 Earnings Conference Call - Final Transcript
Nov 11, 2019 • 04:30 pm ET
Good day, ladies and gentlemen, and welcome to the Rockwell Medical 2019 Q3 Results Conference Call. [Operator Instructions] Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator instructions]
I would now like to turn the conference over to your host, Ms. Judy DiClemente. Please go ahead, madam.
Thank you, Katrina. Welcome to Rockwell Medical's Third Quarter 2019 Earnings Results Call. This is Judy DiClemente of In-Site Communications, Investor Relations representative for Rockwell Medical. Before we begin, I wanted to note that certain matters we will discuss may constitute forward-looking statements within the meaning of the federal securities laws. Words such as may, might, will, should, believe, expect, anticipate, estimate, continue, could, potential, predict, forecast, project, plan, intend, or similar expressions or statements regarding intent, belief or current expectations are forward-looking statements. While Rockwell believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release and which are subject to inherent uncertainty.
These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in Rockwell's SEC filings, many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include statements about the unique J-code for the Triferic powder packet; timing and the success of our NDA submission for IV Triferic; the potential market opportunity for IV Triferic and other Rockwell products; pricing and reimbursement status for IV Triferic, DialySate Triferic and other Rockwell products, including CMS' recently announced final rule regarding eligibility for TDAPA; liquidity and capital resources; expected duration of Rockwell's existing liquidity and working capital; success of our recently announced commercialization plans for Dialysate Triferic; and the success of our efforts to maintain, grow and improve the profitability of our business.
Rockwell expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. This conference call can be accessed on Rockwell Medical's Investor Relations web page. This call is being recorded on November 11, 2019 for audio rebroadcast and can also be accessed on the same web page. Present on today's call are Stuart Paul, President and Chief Executive Officer of Rockwell Medical; Angus Smith, Chief Financial Officer of Rockwell Medical; and John McLaughlin, Chairman of Rockwell Medical's Board of Directors. Stuart and Angus will be available for a question-and-answer session immediately following the call.
At this time, I would like to turn the conference call over to Rockwell's CEO, Stuart Paul. Stuart?
Thank you, Judy and good afternoon, everyone and thank you for joining our call today. I'd like to start today by reminding everyone of Rockwell Medical's mission. We believe we have the potential to transform anemia management in a wide variety of disease states across the globe. And the first disease state that we're